Skip to main content
Media Alert Press Media Alert Press Check a URL
Tuesday, November 10, 2026
Live
Why This CEO Rebuilt His Best-Selling Product Before Taking It to TargetThe FDA now says Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision lossDemocrats press White House on prediction market betting by staffOne mom tallied 23 hours a week of household work. Then she built a company to turn ‘invisible labor’ into a paid professionI Hosted a 26.2-Mile Ruck and Learned the 3 Ownership Tests Every Founder Eventually FacesWorkers Would Take a 10 Percent Pay Cut for Housing Benefits. Only 4 Percent of Employers Offer Them
73,320 Ledger Records 116 added in the last hour1,731 in the last 24 hours
What is counted?

Counted at 18:27:22 UTC. These figures count ledger entries that have a record hash, the same entries as the total. The newest of them was added at 18:12:51 UTC on 2026-11-10. Entries are added in batches when MAP checks its feeds, so the figures vary through the day.

Business

The FDA now says Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss

By Jaimy Lee MarketWatch
The FDA now says Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss

Feed excerpt — reported by MarketWatch

Several medical studies have found that people taking GLP-1 medications have an elevated risk for nonarteritic anterior ischemic optic neuropathy, or NAION.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at MarketWatch →

Original Source

This article was syndicated from MarketWatch. All rights remain with the original publisher.

Powered by CookieAdmin